J. Pippen

发表

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Yuan Qi, W. Fraser Symmans, Lajos Pusztai, 2012, Breast Cancer Research and Treatment.

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

C K Osborne, R. Elledge, C. Osborne, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Saeed Sadeghi, Allison Florance, H. Gómez, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

Phase I I, R andomized, D ouble-Blind S tudy o f T wo D ose L evels of A rzoxifene i n P atients W ith L ocally A dvanced o r M etastatic Breast C ancer

C. Hudis, D. Booser, A. Buzdar, 2003 .

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.

J. Pippen, C. Osborne, A. Barakat, 2011, Breast cancer.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma

C. Osborne, A. Howell, J. Robertson, 2005, Cancer.

Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer.

L. Pusztai, W. Symmans, F. Holmes, 2006, Journal of Clinical Oncology.

Maintenance of Certification: My Perspective.

J. Pippen, 2007, Journal of oncology practice.

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.

F. Holmes, J. Pippen, Stephen E. Jones, 2008, Clinical breast cancer.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.

J. Pippen, Stephen E. Jones, 2005, Clinical breast cancer.

Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer

J. Pippen, S. Vukelja, J. Iglesias, 2011, Breast Cancer Research and Treatment.

Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis.

M. Reed, W. Couser, J. Pippen, 2000, Kidney international.

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.

J. O’Shaughnessy, J. Pippen, T. Marsland, 2004, Clinical breast cancer.

Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

J. O’Shaughnessy, J. Pippen, S. Vukelja, 2002, Clinical breast cancer.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.

N. Robert, P. Ward, J. Pippen, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1).

L. Amler, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time to response: comparison of fulvestrant and oral endocrine agents.

D. Dodwell, J. Pippen, 2006, Clinical breast cancer.

Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer

L. Parker, B. Erikstein, J. Robertson, 2004, Clinical pharmacokinetics.

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.

C. Osborne, L. Mauriac, J. Pippen, 2003, European journal of cancer.

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

F. Holmes, J. O’Shaughnessy, J. Pippen, 2010 .

Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors

N. Senzer, J. Nemunaitis, J. Pippen, 2005, Cancer investigation.

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel.

N. Robert, J. O’Shaughnessy, J. Pippen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Breast Cancer: The Experience of Baylor University Medical Center at Dallas

J. Pippen, J. Goldfarb, 2011, Proceedings.

Giant malignant phyllodes tumor with metastasis to the brain

David M Metter, J. Pippen, C. Osborne, 2019, Proceedings.

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2004 .

Burnout and career satisfaction among US oncologists.

W. Gradishar, J. Sloan, T. Shanafelt, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Mark Yoffe, Debra Patt, D. Patt, 2011, The New England journal of medicine.

Satisfaction with work-life balance and the career and retirement plans of US oncologists.

W. Gradishar, J. Sloan, T. Shanafelt, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

R. Yelensky, J. O’Shaughnessy, J. Pippen, 2015, Cancer medicine.

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

J. Hainsworth, N. Robert, N. Senzer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Yuan Qi, Lajos Pusztai, Charles Coutant, 2011, Journal of the National Cancer Institute.

Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.

H. Gómez, S. Johnston, X. Pivot, 2009 .

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

G. Clark, J. Pippen, Stephen E. Jones, 2002, Clinical breast cancer.

Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.

G. Clark, J. Pippen, R. Mennel, 2001, Clinical breast cancer.

Two Cancers in One: Breast Carcinoma with Underlying Melanoma

J. Pippen, W. Herlihy, Elizabeth Sakach, 2017, Proceedings.

Clinico-radiologic features and management of hematological tumors in the breast: a case series

J. Pippen, Zeeshan A Shah, J. Spigel, 2018, Breast Cancer.

Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.

J. Nemunaitis, J. Pippen, W. Meyer, 1999, Human gene therapy.

Silicone Implants and Breast Cancer

J. Pippen, 1995 .

G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

D. Patt, J. O’Shaughnessy, J. Pippen, 2009 .

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

F. Holmes, J. O’Shaughnessy, B. Hellerstedt, 2018, Cancer medicine.

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

H. Koeppen, F. Holmes, J. O’Shaughnessy, 2015, Clinical Cancer Research.

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

L. Liotta, V. Espina, M. Danso, 2013, BMC Research Notes.

D. Patt, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

L. Liotta, V. Espina, M. Danso, 2013, BMC Research Notes.

Election Reform and Direct Democracy

J. Pippen, S. Bowler, Todd Donovan, 2002 .

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

N. Robert, J. O’Shaughnessy, J. Pippen, 2007, Clinical breast cancer.

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

J. Gralow, J. O’Shaughnessy, J. Pippen, 2010, Clinical breast cancer.

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study.

J. O’Shaughnessy, J. Pippen, S. Jones, 2004, Journal of Clinical Oncology.

Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.

F. Holmes, J. O’Shaughnessy, B. Hellerstedt, 2008, Anticancer research.

The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2005 .

A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. Pippen, S. Jones, J. Blum, 2003 .

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

C. Hudis, D. Booser, A. Buzdar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ICI 182,780 (‘FASLODEX’) 250 mg monthly Intramuscular (I.M.) injection shows consistent Pharmacokinetic (PK) profiles when given as either 1 × 5 ml or 2 × 2.5 ml injections in postmenopausal women with Advanced Breast Cancer (ABC)

B. Erikstein, J. Robertson, J. Pippen, 2001 .

The Sensitivity and Specificity of Sentinel Lymph Node Biopsy for Breast Cancer at Baylor University Medical Center at Dallas: A Retrospective Review of 488 Cases

J. Pippen, D. Savino, M. Punar, 2011, Proceedings.

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Y. Qi, G. Hortobagyi, L. Pusztai, 2011, Journal of the National Cancer Institute.

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.

J. Pippen, C. Osborne, R. Schneider, 2011, Breast cancer.

A medical student perspective on solutions for burnout

J. Pippen, Jonathan H Brewer, C. Gottlich, 2019, Proceedings.

Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study.

A. Makris, X. Pivot, L. Fehrenbacher, 2009 .

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

D. Patt, J. O’Shaughnessy, J. Pippen, 2011, The New England journal of medicine.

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

N. Robert, J. O’Shaughnessy, J. Pippen, 2007, Clinical breast cancer.

Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC).

H. Gómez, M. Koehler, S. Johnston, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008.

H. Gómez, S. Johnston, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.